Amgen Inc AMGN

What the company does

Amgen Inc is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $237.5B, based in the USA.

It employs about 31,500 people and has been listed since Jun 17, 1983.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 27.3 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 10% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 15.6 — they expect higher earnings.

The average analyst price target is 396.70, 10% below the current price (their view, not ours).

The stock sits at 93% of its one-year range (0% = the low, 100% = the high).

The risks

• ⚠️ Net debt is 3.7× shareholders' equity — high leverage.
• • Quarterly report in 9 days (2026-11-03) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 24 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Pays a dividend (2.2% a year).

What changed this week

Over the past week the stock rose 1.6% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

It set a new one-year high this week.

This week's news

• IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER finance.yahoo.com · 2026-10-24
  What the article says

  Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed… source ↗

• Amgen (AMGN) Reports Positive Phase 3 TEZSPIRE Results In Eosinophilic Esophagitis finance.yahoo.com · 2026-10-24
  What the article says

  Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive full Phase 3 results for TEZSPIRE in eosinophilic esophagitis (EoE). The Phase 3 trial showed significant and clinically meaningful improvements in EoE symptoms and endoscopic endpoints sustained through one year. Investigators reported a favorable safety profile… source ↗

• Here's Why Amgen (AMGN) Fell More Than Broader Market finance.yahoo.com · 2026-10-23
  What the article says

  Amgen (AMGN) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%. Shares of the world's largest… source ↗

• BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue. finance.yahoo.com · 2026-10-23
  What the article says

  Oncology-focused biotech firm BeOne Medicines explores buy zone, boosted by strong demand and stellar earnings growth. Continue Reading source ↗

• IBD's 50 Most Sustainable Companies For 2026 finance.yahoo.com · 2026-10-23
  What the article says

  Looking for the best green investments? IBD's 50 Most Sustainable Companies combine high sustainability scores and superior stock ratings. Continue Reading source ↗

• IBD's Most Sustainable Companies Across Industry Categories finance.yahoo.com · 2026-10-23
  What the article says

  Sustainable stocks are ready for a clean energy future and can deliver solid returns in all types of market environments. Continue Reading source ↗

What changed since last week

• New risk flag: earnings report coming up.

• The price rose 3.1% since the last summary.